

## Background


### OUR HOSPITAL

Emergency department



70 beds for short-term stays &  
 200 beds for long-term stays

Contract between the hospital  
 and the Regional Health Agency



Yearly evaluation on medical practices



audit = part of this evaluation

## Purpose

To assess if the prescriptions of prothrombin complex concentrate (PCC) match with official recommendations, with or without anti-vitamin K overdose.

## Materials and Methods

### PRODUCTS of PCC

currently delivered in our hospital

**OCTAPLEX®**  
 &  
**KANOKAD®**

### Data collection form

to assess if the indication and  
 the dosage were correct in each  
 situation

### GUIDELINES

Summary of Products  
 Characteristics and guideline  
 provided by French National  
 Authority for Health (HAS) in 2008

### PATIENTS


Each patient who received PCC  
 from 15 october 2012 till 30  
 september 2013

## Results


14 patient files included




13 correct regarding the indication  
 and 9 regarding the dosage regimen




One case were the administration should not have been  
 given



Man with an unexplained fever for whom a neurological  
 infection was suspected




Received PCC because a lumbar puncture was needed



Had an International Normalized Ratio (INR) at 1,32  
 before the injection whereas the target for such an  
 injection is an INR under 1,5

The dosage regimen was not correct in 4 other cases. In  
 2 of them the standard dose of 1ml per kilogram was  
 given without taking the INR before the injection into  
 account.



## Conclusion

★ Regarding the results the INR before injection of PCC is not always taken into account probably because it is not always available when physician decides to prescribe it.

★ There are some improvements to consider in delay of INR results and sensibilization of physicians about taking the INR before injection into account to calculate the right dose such as writing a protocole to standardize the dosage regimen regarding the product of PCC (Kanokad® or Octaplex®), the indication and the INR before injection.